Literature DB >> 22893587

Hurthle cell carcinoma: a population-level analysis of 3311 patients.

Paolo Goffredo1, Sanziana A Roman, Julie A Sosa.   

Abstract

BACKGROUND: Hurthle cell carcinoma (HCC) is an uncommon and more aggressive thyroid cancer. To date, there is a paucity of data at a population level. In this study, demographic, clinical, and pathologic characteristics of HCC were investigated and compared with other types of differentiated thyroid cancers (ODTCs). The authors also evaluated disease-specific survival and compliance with American Thyroid Association (ATA) management guidelines from 2009.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) database from 1988 to 2009 was used to obtain data on patients with thyroid cancer. Data analyses were performed using chi-square tests, analysis of variance, Kaplan-Meier analysis, binary logistic regression, and Cox proportional hazards regression.
RESULTS: In total, 3311 patients with HCC and 59,585 patients with ODTC were identified. Compared with ODTC, HCC was more common among men (31.1% vs 23.0% for ODTC; P < .001) and among older patients (mean age, 57.6 years vs 48.9 years for ODTC; P < .001). Patients with HCC presented with higher SEER disease stage (P < .001), and their tumors were larger (36.1 mm vs 20.2 mm for ODTC; P < .001). Fewer patients underwent total thyroidectomy (P = .028). Both overall and disease-specific survival were lower for patients with HCC (P < .001), and neither improved over the last 2 decades (P = .689). After adjustment, age ≥45 years, not undergoing surgery, and metastatic disease were strongly associated with a worse prognosis (hazard ratio >3.0). Compliance with recommended surgical treatment according to ATA guidelines was lower among patients with HCC aged ≥65 years (odds ratio [OR], 1.43; P = .002) and among unmarried patients (OR, 1.29; P = .004). Predictors of noncompliance with ATA guidelines for treatment with radioactive implants or radioisotopes were age ≥65 years (OR, 1.31; P = .017), diagnosis between 1988 and 1997, no surgery, and partial thyroidectomy (OR, 1.81, 19.48, and 4.02, respectively; P < .001).
CONCLUSIONS: HCC has more aggressive behavior and compromised survival compared with ODTC. The current results indicated that it may be important to consider a different staging system or separate practice guidelines.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22893587     DOI: 10.1002/cncr.27770

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  Thyroid Hürthle cell tumors: research of potential markers of malignancy.

Authors:  G Donatini; A Beaulieu; M Castagnet; J-L Kraimps; P Levillain; G Fromont
Journal:  J Endocrinol Invest       Date:  2015-07-19       Impact factor: 4.256

Review 2.  Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma.

Authors:  Tyler Janovitz; Justine A Barletta
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

3.  Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases.

Authors:  Bin Xu; Laura Wang; R Michael Tuttle; Ian Ganly; Ronald Ghossein
Journal:  Hum Pathol       Date:  2015-09-16       Impact factor: 3.466

4.  MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.

Authors:  Katayoon Kasaian; Ana-Maria Chindris; Sam M Wiseman; Karen L Mungall; Thomas Zeng; Kane Tse; Jacqueline E Schein; Michael Rivera; Brian M Necela; Jennifer M Kachergus; John D Casler; Andrew J Mungall; Richard A Moore; Marco A Marra; John A Copland; E Aubrey Thompson; Robert C Smallridge; Steven J M Jones
Journal:  J Clin Endocrinol Metab       Date:  2015-01-27       Impact factor: 5.958

5.  Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature.

Authors:  Moira Ragazzi; Federica Torricelli; Benedetta Donati; Alessia Ciarrocchi; Dario de Biase; Giovanni Tallini; Eleonora Zanetti; Alessandra Bisagni; Elisabetta Kuhn; Davide Giordano; Andrea Frasoldati; Simonetta Piana
Journal:  Virchows Arch       Date:  2020-07-18       Impact factor: 4.064

6.  Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.

Authors:  Vera Wenter; Annamirl Jellinek; Marcus Unterrainer; Freba Ahmaddy; Sebastian Lehner; Nathalie Lisa Albert; Peter Bartenstein; Thomas Knösel; Christine Spitzweg; Harun Ilhan; Andrei Todica
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

Review 7.  Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Authors:  Zubair W Baloch; Sylvia L Asa; Justine A Barletta; Ronald A Ghossein; C Christofer Juhlin; Chan Kwon Jung; Virginia A LiVolsi; Mauro G Papotti; Manuel Sobrinho-Simões; Giovanni Tallini; Ozgur Mete
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 3.943

8.  Development and validation of a prognostic nomogram for Hürthle cell thyroid carcinoma: a SEER-based study.

Authors:  Cong Shen; Yunzhe Zhao; Xiangyuan Qiu; Peng Li; Ying Ding; Wenlong Wang; Botao Sun; Xinying Li; Wei Jiang
Journal:  Gland Surg       Date:  2022-03

9.  PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma.

Authors:  Shuanzeng Wei; Virginia A LiVolsi; Kathleen T Montone; Jennifer J D Morrissette; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

10.  METASTATIC HÜRTHLE CELL CARCINOMA PRESENTING WITH LOW FREE THYROXINE, SEVERE HYPERCALCEMIA AND SPURIOUS GROWTH HORMONE PRODUCTION.

Authors:  S Rehman; K K Dhatariya
Journal:  AACE Clin Case Rep       Date:  2019-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.